From Name:
From Email:
To Name:
To Email:

Optional Message:


FDA Review Finds Long-term Treatment With Clopidogrel Does Not Change Risk of Death

from U.S. Food and Drug Administration

The U.S. Food and Drug Administration (FDA) recently issued a Drug Safety Communication on Plavix (clopidogrel) that narrowed its indication for use, specifically determining that it does not increase or decrease risk of death in patients with heart disease. This update was issued following an FDA review of the dual anti-platelet therapy trial and other large long-term clinical trials of clopidogrel. Patients are not advised to stop taking clopidogrel due to an increased risk of heart attack and blood clots, and providers are urged to consider the benefits and risks associated with available anti-platelet medications before initiating treatment. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063